Evaluation of 68Ga-FAPI radiotracer in lung cancer

Evaluation of the diagnostic value of 68Ga-FAPI radiotracer compared with 18F-FDG in PET/CT scans of patients with non-small cell lung cancer- a pilot study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220817055732N1

Enrollment

Registered

2022-09-26

Start date

2022-10-23

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer. Malignant neoplasm of bronchus and lung

Interventions

Intervention 1: Intervention group: patients with lung cancer referred to this center after 18F-FDG are selected non-randomly after receiving full explanations and personal consent to perform a secon

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A patient with lung cancer proven in pathology A patient with lung cancer in the staging phase

Exclusion criteria

Exclusion criteria: Patients do not accept the offer of PET-CT with 68Ga-FAPI radiopharmaceutical after providing the necessary explanations and answering their questions. Patients withdraw from the study before the scan. Uncontrolled diseases (such as fatal arrhythmias) that require hospitalization. Suffering from mental illnesses that take away the ability to make decisions and cooperate. Pregnant or lactating women. Suffering from physical diseases that disrupt the imaging process. The death of the patient in the interval between the two studied scans. History of cancer other than lung cancer History of active inflammatory/infectious disease

Design outcomes

Primary

Measure	Time frame
The number of malignant lesions in selected patients. Timepoint: After PET-CT imaging of the patients with 18FDG and 68Ga-FAPI radiotracers. Method of measurement: Investigation of PET-CT scans.;Localization of malignant lesions in selected patients. Timepoint: After PET-CT imaging of the patients with 18FDG and 68Ga-FAPI radiotracers. Method of measurement: Investigation of PET-CT scans.;Size of malignant lesions in selected patients. Timepoint: After PET-CT imaging of the patients with 18FDG and 68Ga-FAPI radiotracers. Method of measurement: Investigation of PET-CT scans.;Shape of malignant lesions in selected patients. Timepoint: After PET-CT imaging of the patients with 18FDG and 68Ga-FAPI radiotracers. Method of measurement: Investigation of PET-CT scans.	—

Measure

Time frame

The number of malignant lesions in selected patients. Timepoint: After PET-CT imaging of the patients with 18FDG and 68Ga-FAPI radiotracers. Method of measurement: Investigation of PET-CT scans.;Localization of malignant lesions in selected patients. Timepoint: After PET-CT imaging of the patients with 18FDG and 68Ga-FAPI radiotracers. Method of measurement: Investigation of PET-CT scans.;Size of malignant lesions in selected patients. Timepoint: After PET-CT imaging of the patients with 18FDG and 68Ga-FAPI radiotracers. Method of measurement: Investigation of PET-CT scans.;Shape of malignant lesions in selected patients. Timepoint: After PET-CT imaging of the patients with 18FDG and 68Ga-FAPI radiotracers. Method of measurement: Investigation of PET-CT scans.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contacthossein behnam-manesh

Shahid Beheshti University of Medical Sciences

h_behnam@sbmu.ac.ir+98 21 2712 2701

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026